Literature DB >> 17030589

Screening designs for drug development.

David Rossell1, Peter Müller, Gary L Rosner.   

Abstract

We propose drug screening designs based on a Bayesian decision-theoretic approach. The discussion is motivated by screening designs for phase II studies. The proposed screening designs allow consideration of multiple treatments simultaneously. In each period, new treatments can arise and currently considered treatments can be dropped. Once a treatment is removed from the phase II screening trial, a terminal decision is made about abandoning the treatment or recommending it for a future confirmatory phase III study. The decision about dropping treatments from the active set is a sequential stopping decision. We propose a solution based on decision boundaries in the space of marginal posterior moments for the unknown parameter of interest that relates to each treatment. We present a Monte Carlo simulation algorithm to implement the proposed approach. We provide an implementation of the proposed method as an easy to use R library available for public domain download (http://www.stat.rice.edu/~rusi/ or http://odin.mdacc.tmc.edu/~pm/).

Entities:  

Mesh:

Year:  2006        PMID: 17030589     DOI: 10.1093/biostatistics/kxl031

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  9 in total

1.  Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot.

Authors:  Byron J Gajewski; Scott M Berry; Melanie Quintana; Mamatha Pasnoor; Mazen Dimachkie; Laura Herbelin; Richard Barohn
Journal:  Stat Med       Date:  2015-01-07       Impact factor: 2.373

2.  Clinical Trial Design as a Decision Problem.

Authors:  Peter Müller; Yanxun Xu; Peter F Thall
Journal:  Appl Stoch Models Bus Ind       Date:  2017-01-13       Impact factor: 1.338

3.  Bayesian decision analysis for choosing between diagnostic/prognostic prediction procedures.

Authors:  John Kornak; Ying Lu
Journal:  Stat Interface       Date:  2011       Impact factor: 0.582

4.  Bayesian adaptive phase II screening design for combination trials.

Authors:  Chunyan Cai; Ying Yuan; Valen E Johnson
Journal:  Clin Trials       Date:  2013-01-28       Impact factor: 2.486

5.  Bayesian Methods in Regulatory Science.

Authors:  Gary L Rosner
Journal:  Stat Biopharm Res       Date:  2019-10-29       Impact factor: 1.452

6.  Bayesian optimal design for phase II screening trials.

Authors:  Meichun Ding; Gary L Rosner; Peter Müller
Journal:  Biometrics       Date:  2007-12-20       Impact factor: 1.701

Review 7.  Decision-theoretic designs for small trials and pilot studies: A review.

Authors:  Siew Wan Hee; Thomas Hamborg; Simon Day; Jason Madan; Frank Miller; Martin Posch; Sarah Zohar; Nigel Stallard
Journal:  Stat Methods Med Res       Date:  2015-06-05       Impact factor: 3.021

8.  Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution.

Authors:  Siew Wan Hee; Nicholas Parsons; Nigel Stallard
Journal:  Biom J       Date:  2017-07-26       Impact factor: 2.207

9.  Sequential stopping for high-throughput experiments.

Authors:  David Rossell; Peter Müller
Journal:  Biostatistics       Date:  2012-08-20       Impact factor: 5.899

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.